We serve Chemical Name:N-butylcyclohexylamine CAS:10108-56-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N-butylcyclohexylamine
CAS.NO:10108-56-2
Synonyms:N-Butylcyclohexaylamine;N-cyclohexylbutylamine;butyl cyclohexylamine;Cyclohexylbutylamine;N-n-butylcyclohexylamine;EINECS 233-294-6
Molecular Formula:C10H21N
Molecular Weight:155.28000
HS Code:2921300090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:209.3ºC at 760mmHg
Density:0.84g/cm3
Index of Refraction:1.456
PSA:12.03000
Exact Mass:155.16700
LogP:3.09970
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N-Butylcyclohexaylamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 233-294-6 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-Butylcyclohexaylamine Use and application,N-Butylcyclohexaylamine technical grade,usp/ep/jp grade.
Related News: From a global perspective, China’s API companies have also performed well. According to the report of the American Transparent Medicine website, in 2016 the top ten pharmaceutical companies in the global API market, Chinese pharmaceutical companies accounted for 6 seats. N-butylcyclohexylamine manufacturer The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. N-butylcyclohexylamine supplier From a global perspective, China’s API companies have also performed well. According to the report of the American Transparent Medicine website, in 2016 the top ten pharmaceutical companies in the global API market, Chinese pharmaceutical companies accounted for 6 seats. N-butylcyclohexylamine vendor China has a complete upstream and downstream industry chain, lower costs, and good talent reserves. It is one of the few industries in China that has an advantage in international competition. N-butylcyclohexylamine factory Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs.
